

22nd June 2005

**Attention: Mr Scott Evans**  
**General Manager, NSX Ltd**  
Fax: 49291556  
Email: mail@newsx.com.au  
Pages: 14 (including cover)

**RE: Application for Quotation of Additional Securities**

Dear Scott,

Herewith the further application for quotation of additional securities, as advised in our letter of the 20<sup>th</sup>, in relation to the 15,000,000 shares to be issued pursuant to the ENSI-Med transaction.

Regards,

A handwritten signature in dark ink, appearing to be 'BD' followed by a horizontal line and a dot.

Bronte Douglass

# Application for Quotation of Additional Securities

File Reference:

I:\Issuers\Listed\Cosmedics Australia\Application for Quotation of Additional Securities 21 june 2005.doc



# **Table of Contents**

<b>INTRODUCTION .....</b>	<b>3</b>
MORE INFORMATION AND SUBMISSION OF FORM: .....	3
<b>NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT .....</b>	<b>4</b>
<b>PART 1 - ALL ISSUES.....</b>	<b>4</b>
<b>PART 2 - BONUS ISSUE OR PRO RATA ISSUE.....</b>	<b>7</b>
<b>PART 3 - QUOTATION OF SECURITIES .....</b>	<b>9</b>
ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES .....	9
<b>QUOTATION AGREEMENT .....</b>	<b>11</b>

## Introduction

To ensure the efficient processing of this form by NSX, please:

1. Adhere to the suggested number of the annexures required by this form.
2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).

### More Information and Submission of Form:

Further information can be obtained from and all applications should be sent to:

Manager, Admissions  
Stock Exchange of Newcastle Limited  
PO BOX 283  
Newcastle NSW 2300

Phone: 61 2 4929 6377

Fax: 61 2 4929 1556

<http://www.newsx.com.au>

# New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.*

Introduced 11 March 2004.

Name of entity

COSMEDICS AUSTRALIA LIMITED

ABN/ACN

38 002 862 017

We (the entity) give NSX the following information.

## Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |   |
|---|---|---|
| 1 | Class of securities issued or to be issued  | Ordinary shares   |
| 2 | Number of securities issued or to be issued (if known) or maximum number which may be issued  | 15,000,000 Ordinary Shares                              |
| 3 | Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion) | Fully paid shares to rank equally with existing shares. |

4	<p>Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"><li>• the date from which they do</li><li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li><li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li></ul>	All Ordinary Shares issued rank equally.								
5	Issue price or consideration	15,000,000 shares to be issued at 20 cents each pursuant to shareholder authority obtained via resolutions 2 and 4 at the shareholder meeting of 9 June 2005.								
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Consideration for the purchase of the Ensi Med assets, being all the plant and equipment used in the conduct of the Ensi Med business, all stock in trade incl 400,000 safety syringes, all contracts, all regulatory approvals etc. These assets relate to the manufacture of the patented safety syringe.								
7	Dates of entering securities into uncertificated holdings or despatch of certificates	Within 5 days of the settlement of the purchase agreement with Ensi Med.								
8	Number and class of all securities quoted on NSX (including the securities in clause 2 if applicable)	<table><tr><th>Number</th><th>Class</th></tr><tr><td>36,315,016</td><td rowspan="2">Ordinary shares, subject to any restriction placed on the 15,000,000 shares in clause 2</td></tr><tr><td>4,991,259</td></tr><tr><td></td><td>December 05 options</td></tr></table>	Number	Class	36,315,016	Ordinary shares, subject to any restriction placed on the 15,000,000 shares in clause 2	4,991,259		December 05 options	
Number	Class									
36,315,016	Ordinary shares, subject to any restriction placed on the 15,000,000 shares in clause 2									
4,991,259										
	December 05 options									

<b>9</b> Number and class of all securities not quoted on NSX ( <i>including</i> the securities in clause 2 if applicable)	Number	Class
	16,500,000	Ordinary shares
	18,821,251	escrowed December 05 options
	1,250,000	escrowed December 07 options (not currently listed)
	15,925,000	December 07 options (not currently listed)
<b>10</b> Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Should any of the 15,000,000 shares described in clause 2 be subject to escrow restrictions, they would not be included in in the number of shares in clause 8, above.	
	All ordinary shares rank equally for any future dividends	

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the securities will be offered	N/A
14	Class of securities to which the offer relates	N/A
15	Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new issue documents  <small>Note: Security holders must be told how their entitlements are to be dealt with.</small>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A



<b>25</b>	If the issue is contingent on security holders' approval, the date of the meeting	N/A
<b>26</b>	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
<b>27</b>	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
<b>28</b>	Date rights trading will begin (if applicable)	N/A
<b>29</b>	Date rights trading will end (if applicable)	N/A
<b>30</b>	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
<b>31</b>	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
<b>32</b>	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
<b>33</b>	Despatch date	N/A

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

**34** Type of securities  
(tick one)

(a) ☒ Securities described in Part 1 (Depending upon any escrow conditions placed on any of those shares by the NSX)

(b) ☐ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

**35** ☒ If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders (SEE APPENDIX)

**36** ☒ If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories

Nil	(1 - 1,000)
Nil	(1,001 - 5,000)
2	(5,001 - 10,000)
23	(10,001 - 100,000)
9	(100,001 and over)

**37** ☐ A copy of any trust deed for the additional securities

Entities that have ticked box 34(b)

**38** Number of securities for which quotation is sought

N/A
-----

**39** Class of securities for which quotation is sought

N/A
-----

<p><b>40</b> Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>N/A</p>					
<p><b>41</b> Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another security, clearly identify that other security)</p>	<p>N/A</p>					
<p><b>42</b> Number and class of all securities quoted on NSX (<i>including</i> the securities in clause 38)</p>	<table border="1"> <thead> <tr> <th data-bbox="795 966 1071 1018">Number</th> <th data-bbox="1071 966 1354 1018">Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="795 1018 1071 1199">N/A</td> <td data-bbox="1071 1018 1354 1199"></td> </tr> </tbody> </table>	Number	Class	N/A		
Number	Class					
N/A						

## Quotation agreement

1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.

2 We warrant the following to NSX.

- The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those securities should not be granted quotation.
- An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

**Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty**

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:

Date: 21/6/05

(Director)

Print name: DR BRONTE DOUGLASS

**APPENDIX. 20 LARGEST HOLDERS OF THE ADDITIONAL SECURITIES**

<b>Name</b>	<b>No. of Shares</b>	<b>Percentage of Issued Capital after the issue of these 15,000,000 shares</b>
<b>1</b> Ensi Med International Pty Limited	3,735,869	7.07
<b>2</b> Ensi Med Manufacturing Pty Limited	3,735,869	7.07
<b>3</b> Clarke & Bradly Computer Services Pty Limited	1,858,498	3.52
<b>4</b> Send Judah First Pty Limited	1,710,073	3.24
<b>5</b> Geoff Cowan & Associates Pty Limited	1,144,473	2.17
<b>6</b> LAH Securities Pty Ltd	798,719	1.51
<b>7</b> Safety Syringe Pty Limited	356,374	0.67
<b>8</b> JHRW PTY LTD as Trustee of the JHRW Family Trust	266,666	0.50
<b>9</b> Graeme Johnston & Stephanie Coutant	133,333	0.25
<b>10</b> Mikas Svazas	100,000	0.19
<b>11</b> Aleksas Svazas	100,000	0.19
<b>12</b> Kazimeras Svazas	100,000	0.19
<b>13</b> Andrew Johnson Investments	100,000	0.19
<b>14</b> Sunny Dhammapala	93,333	0.18
<b>15</b> Shame Hamill	80,000	0.15
<b>16</b> JND Maintenance	66,666	0.13
<b>17</b> Vic Car Loans Staff Superannuation Fund	66,666	0.13
<b>18</b> Ray Ward	66,666	0.13
<b>19</b> Geoff Mathers	66,666	0.13
<b>20</b> The Rose and Associates Superannuation Fund	66,666	0.13